Ionis Pharmaceuticals Gross Profit Growth & History (IONS)
Ionis Pharmaceuticals's gross profit was $927.8M for fiscal 2025.
View full Ionis Pharmaceuticals company overviewIonis Pharmaceuticals annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $927.8M | $233.9M | +33.70% |
| 2024 | 2024-12-31 | $693.9M | −$84.6M | −10.87% |
| 2023 | 2023-12-31 | $778.5M | $205.3M | +35.81% |
| 2022 | 2022-12-31 | $573.3M | −$226.4M | −28.31% |
| 2021 | 2021-12-31 | $799.6M | $82.3M | +11.47% |
| 2020 | 2020-12-31 | $717.3M | −$400.9M | −35.85% |
| 2019 | 2019-12-31 | $1.12B | $520.4M | +87.04% |
| 2018 | 2018-12-31 | $597.9M | $83.7M | +16.27% |
| 2017 | 2017-12-31 | $514.2M | $141.4M | +37.93% |
| 2016 | 2016-12-31 | $372.8M | — | — |
Ionis Pharmaceuticals quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $265.2M | −$182.7M | −40.79% |
| Q1 2026 | 2026-03-31 | $243.1M | $113.0M | +86.79% |
| Q4 2025 | 2025-12-31 | $195.4M | −$27.4M | −12.29% |
| Q3 2025 | 2025-09-30 | $154.4M | $21.6M | +16.30% |
| Q2 2025 | 2025-06-30 | $447.9M | $226.8M | +102.59% |
| Q1 2025 | 2025-03-31 | $130.1M | $12.8M | +10.91% |
| Q4 2024 | 2024-12-31 | $222.7M | −$98.7M | −30.70% |
| Q3 2024 | 2024-09-30 | $132.7M | −$9.3M | −6.53% |
| Q2 2024 | 2024-06-30 | $221.1M | $35.2M | +18.94% |
| Q1 2024 | 2024-03-31 | $117.3M | −$11.8M | −9.16% |
| Q4 2023 | 2023-12-31 | $321.4M | $173.2M | +116.89% |
| Q3 2023 | 2023-09-30 | $142.0M | −$16.2M | −10.26% |
| Q2 2023 | 2023-06-30 | $185.9M | $56.8M | +44.04% |
| Q1 2023 | 2023-03-31 | $129.2M | −$8.6M | −6.22% |
| Q4 2022 | 2022-12-31 | $148.2M | −$289.6M | −66.15% |
| Q3 2022 | 2022-09-30 | $158.3M | $28.2M | +21.72% |
| Q2 2022 | 2022-06-30 | $129.0M | $6.3M | +5.09% |
| Q1 2022 | 2022-03-31 | $137.7M | $28.7M | +26.34% |
| Q4 2021 | 2021-12-31 | $437.8M | $150.8M | +52.55% |
| Q3 2021 | 2021-09-30 | $130.0M | −$27.0M | −17.18% |
| Q2 2021 | 2021-06-30 | $122.8M | −$19.7M | −13.85% |
| Q1 2021 | 2021-03-31 | $109.0M | −$21.8M | −16.66% |
| Q4 2020 | 2020-12-31 | $287.0M | −$205.7M | −41.75% |
| Q3 2020 | 2020-09-30 | $157.0M | −$9.9M | −5.95% |
| Q2 2020 | 2020-06-30 | $142.5M | −$19.9M | −12.26% |
| Q1 2020 | 2020-03-31 | $130.8M | −$165.4M | −55.83% |
| Q4 2019 | 2019-12-31 | $492.7M | $302.4M | +158.90% |
| Q3 2019 | 2019-09-30 | $166.9M | $21.5M | +14.81% |
| Q2 2019 | 2019-06-30 | $162.4M | $44.7M | +37.96% |
| Q1 2019 | 2019-03-31 | $296.2M | $151.8M | +105.08% |
| Q4 2018 | 2018-12-31 | $190.3M | — | — |
| Q3 2018 | 2018-09-30 | $145.4M | — | — |
| Q2 2018 | 2018-06-30 | $117.7M | — | — |
| Q1 2018 | 2018-03-31 | $144.4M | — | — |
Ionis Pharmaceuticals gross profit trends
Over the last five fiscal years, Ionis Pharmaceuticals's gross profit increased from $717.3M to $927.8M, a change of $210.5M. The latest reported quarter, Q2 2026, shows $265.2M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ionis Pharmaceuticals source filings ↗